Quotient Sciences, Biorasi Partner to Accelerate Early Phase Clinical Trials

Quotient Sciences, a global drug development, research and manufacturing accelerator, and Biorasi, a global clinical research organization (CRO), have partnered to deliver fully integrated early phase clinical trial solutions.

The partnership will combine Quotient Sciences’ expertise in early clinical development with Biorasi’s global patient recruitment capabilities to provide biotech and pharma Sponsors with a simplified, efficient pathway from Investigational New Drug (IND) to proof-of-concept (POC) with seamless transitions from healthy volunteers into patient groups within first-in-human (FIH) Phase I/IIa clinical trials.

Sponsors will benefit from Quotient Sciences’ clinical pharmacology expertise, with facilities in Miami (U.S.) and Nottingham (UK) comprising 230 beds and supported by a large database of trial participants. This is complemented by Biorasi’s global patient recruitment network, which spans a wide range of therapeutic areas including dermatology, neurology, nephrology, cell therapy, and other specialty fields.

The partnership will provide sponsors with a single provider model for FIH to POC programs, with the option of a single contract and a unified protocol and regulatory submissions to reduce the outsourcing complexity and accelerate development timelines.

Thierry Van Nieuwenhove, CEO of Quotient Sciences, said: “By combining Quotient’s clinical expertise with Biorasi’s global patient access network, we enable Sponsors to efficiently conduct early-phase studies under a single operational and contracting model, while maintaining the highest standards of clinical research and data quality.”

“Biotech and pharma innovators need flexible, reliable solutions to succeed in today’s evolving clinical trial environment,” added Chris O’Brien, CEO of Biorasi. “Through this collaboration with Quotient Sciences, we are providing Sponsors with a simplified, scalable model that supports everything from FIH studies to patient POC, helping new therapies reach patients faster.”